In the univariate analysis, both KRAS and BRAF mutations were more frequent in older patients (P < 0.05), and female patients shared higher KRAS mutations (codon 12 and codon 61) frequency, meanwhile patients with tumor family history showed more KRAS (G12D) mutations (30.4% vs. 11.8%, P = 0.023) and stage II tumors harbored a higher KRAS codon 13 mutations (10.5% vs. 1.9%, P = 0.013). This evidence concerns the gene KRAS and neoplasm.